Browse > Article
http://dx.doi.org/10.5483/BMBRep.2016.49.1.201

Rapamycin-resistant and torin-sensitive mTOR signaling promotes the survival and proliferation of leukemic cells  

Park, Seohyun (Department of Biomedical Science, College of Natural Science, Hallym University)
Sim, Hyunsub (Department of Biomedical Science, College of Natural Science, Hallym University)
Lee, Keunwook (Department of Biomedical Science, College of Natural Science, Hallym University)
Publication Information
BMB Reports / v.49, no.1, 2016 , pp. 63-68 More about this Journal
Abstract
The serine/threonine kinase mTOR is essential for the phosphoinositide 3-kinases (PI3K) signaling pathway, and regulates the development and function of immune cells. Aberrant activation of mTOR signaling pathway is associated with many cancers including leukemia. Here, we report the contributions of mTOR signaling to growth of human leukemic cell lines and mouse T-cell acute leukemia (T-ALL) cells. Torin, an ATP-competitive mTOR inhibitor, was found to have both cytotoxic and cytostatic effects on U-937, THP-1, and RPMI-8226 cells, but not on Jurkat or K-562 cells. All cells were relatively resistant to rapamycin even with suppressed activity of mTOR complex 1. Growth of T-ALL cells induced by Notch1 was profoundly affected by torin partially due to increased expression of Bcl2l11 and Bbc3. Of note, activation of Akt or knockdown of FoxO1 mitigated the effect of mTOR inhibition on T-ALL cells. Our data provide insight on the effect of mTOR inhibitors on the survival and proliferation of leukemic cells, thus further improving our understanding on cell-context-dependent impacts of mTOR signaling. [BMB Reports 2016; 49(1): 63-68]
Keywords
mTOR; torin; rapamycin; leukemic cell; T-ALL;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Badura S, Tesanovic T, Pfeifer H et al (2013) Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia. PLoS One 8, e80070   DOI
2 Wan X, Harkavy B, Shen N, Grohar P and Helman LJ (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26, 1932-1940   DOI
3 Feldman ME, Apsel B, Uotila A et al (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7, e38   DOI
4 Sarbassov DD, Ali SM, Sengupta S et al (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22, 159-168   DOI
5 Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP and Baldwin AS (2008) Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev 22, 1490-1500   DOI
6 Wang P, Qiu W, Dudgeon C et al (2009) PUMA is directly activated by NF-kappaB and contributes to TNF-alpha-induced apoptosis. Cell Death Differ 16, 1192-1202   DOI
7 Brunet A, Bonni A, Zigmond MJ et al (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857-868   DOI
8 Tamburini J, Elie C, Bardet V et al (2007) Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood 110, 1025-1028   DOI
9 Hoshii T, Kasada A, Hatakeyama T et al (2014) Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells. Proc Natl Acad Sci U S A 111, 3805-3810   DOI
10 Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9, 550-562   DOI
11 Bertacchini J, Heidari N, Mediani L et al (2015) Targeting PI3K/AKT/mTOR network for treatment of leukemia. Cell Mol Life Sci 72, 2337-2347   DOI
12 Silva A, Yunes JA, Cardoso BA et al (2008) PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 118, 3762-3774   DOI
13 Magee JA, Ikenoue T, Nakada D, Lee JY, Guan KL and Morrison SJ (2012) Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. Cell Stem Cell 11, 415-428   DOI
14 Kalaitzidis D, Sykes SM, Wang Z et al (2012) mTOR complex 1 plays critical roles in hematopoiesis and Pten-lossevoked leukemogenesis. Cell Stem Cell 11, 429-439   DOI
15 Xu Q, Thompson JE and Carroll M (2005) mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 106, 4261-4268   DOI
16 Simioni C, Cani A, Martelli AM et al (2014) Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. Oncotarget 5, 10034-10047   DOI
17 Zeng H and Chi H (2013) mTOR and lymphocyte metabolism. Curr Opin Immunol 25, 347-355   DOI
18 Lee K, Gudapati P, Dragovic S et al (2010) Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 32, 743-753   DOI
19 Powell JD, Pollizzi KN, Heikamp EB and Horton MR (2012) Regulation of immune responses by mTOR. Annu Rev Immunol 30, 39-68   DOI
20 Laplante M and Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149, 274-293   DOI
21 Lee K, Heffington L, Jellusova J et al (2013) Requirement for Rictor in homeostasis and function of mature B lymphoid cells. Blood 122, 2369-2379   DOI
22 Lee K, Nam KT, Cho SH et al (2012) Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia. J Exp Med 209, 713-728   DOI
23 Weichhart T, Hengstschlager M and Linke M (2015) Regulation of innate immune cell function by mTOR. Nat Rev Immunol 15, 599-614   DOI